Vivos Therapeutics Inc expected to post a loss of $1.90 a share - Earnings Preview

Vivos Therapeutics

26/03/2024 11:06

* Vivos Therapeutics Inc  VVOS.OQ   VVOS.O  is expected
to show a
fall in quarterly revenue when it reports  results on March 28
(estimated) for the period ending December 31 2023
    * The Littleton Colorado-based  company is expected to
report a
13.8% decrease in revenue to $3.406 million from $3.95 million a
year ago, according to the mean estimate from 2 analysts, based
on LSEG data.
    * ​LSEG's mean analyst estimate for Vivos Therapeutics Inc
is for
a loss of $1.90 per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Vivos
Therapeutics Inc is $7.13​, above​ its last closing price
of $4.55. ​​​

This summary was machine generated March 26 at 11:06 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)